Passage Bio To Present At 2022 Wedbush Pacgrow Healthcare Vi...| MENAFN.COM

Saturday, 13 August 2022 07:04 GMT

Passage Bio To Present At 2022 Wedbush Pacgrow Healthcare Virtual Conference

(MENAFN- GlobeNewsWire - Nasdaq)

PHILADELPHIA, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that Simona King, chief financial officer of Passage Bio, will participate in a virtual panel discussion at the upcoming 2022 Wedbush PacGrow Healthcare Virtual Conference being held from August 9-10, 2022.

Format: Panel Discussion
Title: Headspace - Updates in CNS Gene Therapy
Date: Tuesday, August 9, 2022
Time: 8:35 a.m. ET

A live webcast of the event will be available on the Investors & Media section of Passage Bio's website at . A replay of the presentation will be available for 30 days following the event.

About Passage Bio

Passage Bio (Nasdaq: PASG) is a clinical-stage genetic medicines company on a mission to provide life-transforming therapies for patients with CNS diseases with limited or no approved treatment options. Our portfolio spans pediatric and adult CNS indications, and we are currently advancing three clinical programs in GM1 gangliosidosis, Krabbe disease and frontotemporal dementia with several additional programs in preclinical development. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania's Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. Through this collaboration, we have enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at .

For further information, please contact:

Passage Bio Investors:
Stuart Henderson
Passage Bio

Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.